CHARLOTTE, N.C. - An expert on the Food and Drug Administration is not qualified to testify about defendant Novartis Pharmaceuticals' Corp.'s conduct regarding approvals and post-approval of new drug applications or the drug maker's communication to health care providers of the risks of osteonecrosis of the jaw (ONJ), a North Carolina federal judge hearing the Aredia and Zometa multidistrict litigation held March 21 ( Betty Lemons v. Novartis Pharmaceuticals, No. 3:08-cv-00361, W.D. N.C.; 2012 U.S. Dist. LEXIS 38053).
Lexis.com subscribers may access Litigation Practice & Procedure, Personal Injury and Products Liability resources on Lexis.com. Mealey's subscribers may search Mealey's Litigation Reports by Practice Area. AdditionalLitigation and Products Liability resources including Emerging Issues Analysis are available in the LexisNexis Store.